Experts in treating a rare group of cancers that affect tissues such as muscle, fat, nerves and the gastrointestinal wall are meeting in Milan, Italy on 13-14 May to discuss the latest information on how these diseases develop and potential new avenues for therapy.
The 2nd Symposium on Sarcoma and GIST (Gastrointestinal Stromal Tumors) organized by the European Society for Medical Oncology (ESMO), will include sessions on the genetics of sarcomas, on understanding how drug resistance develops and possibilities for new treatment options.
There will be a particular focus on how scientists and clinicians can work together to develop new treatments, including molecular targeted therapies. The theme of the meeting is 'Insights at the crossroads of molecular biology, pathology and clinic.'
"Sarcomas are relatively rare, but they are serving as a model for the way new molecular targeted therapies are being introduced into clinical practice," said co-chair of the event Dr. Paolo G. Casali, Head of the Sarcoma Medical Treatment Unit at the Milan Istituto Nazionale Tumori and Chair of the ESMO Sarcoma Working Group. "This challenges our ability to combine information from as diverse areas as biology, pathology and the clinic to achieve better results for patients."
"The molecular and pathological bases represent extremely valuable diagnostic and prognostic information for the proper treatment of this disease, although the way we can exploit all these data in the clinic is still to be defined properly," said co-chair Dr. Paolo Dei Tos, Director of the Pathology Unit of the Regional Hospital of Treviso, Italy.
Sarcomas are cancers of the connective or supportive tissues, such as muscles, tendons, ligaments, nerves, fat and blood vessels, therefore they can arise everywhere in the body, although they are rare. Sarcomas are also different to the much more frequent carcinomas of the breast, colon, lung, and others.
|Contact: Vanessa Pavinato|
European Society for Medical Oncology